+

WO2000042068A3 - Hiv related peptides - Google Patents

Hiv related peptides Download PDF

Info

Publication number
WO2000042068A3
WO2000042068A3 PCT/US2000/000372 US0000372W WO0042068A3 WO 2000042068 A3 WO2000042068 A3 WO 2000042068A3 US 0000372 W US0000372 W US 0000372W WO 0042068 A3 WO0042068 A3 WO 0042068A3
Authority
WO
WIPO (PCT)
Prior art keywords
related peptides
hiv
hiv related
antibodies
epitopes
Prior art date
Application number
PCT/US2000/000372
Other languages
French (fr)
Other versions
WO2000042068A9 (en
WO2000042068A2 (en
Inventor
Giuseppe Scala
Xueni Chen
Oren J Cohen
Anthony Fauci
Original Assignee
Us Gov Health & Human Serv
Giuseppe Scala
Xueni Chen
Oren J Cohen
Anthony Fauci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Giuseppe Scala, Xueni Chen, Oren J Cohen, Anthony Fauci filed Critical Us Gov Health & Human Serv
Priority to US09/869,003 priority Critical patent/US6911527B1/en
Priority to AU26031/00A priority patent/AU2603100A/en
Priority to EP00904245A priority patent/EP1159297A2/en
Publication of WO2000042068A2 publication Critical patent/WO2000042068A2/en
Publication of WO2000042068A3 publication Critical patent/WO2000042068A3/en
Publication of WO2000042068A9 publication Critical patent/WO2000042068A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.
PCT/US2000/000372 1999-01-11 2000-01-07 Hiv related peptides WO2000042068A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/869,003 US6911527B1 (en) 1999-01-11 2000-01-07 HIV related peptides
AU26031/00A AU2603100A (en) 1999-01-11 2000-01-07 Novel hiv related peptides
EP00904245A EP1159297A2 (en) 1999-01-11 2000-01-07 Hiv related peptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11543099P 1999-01-11 1999-01-11
US60/115,430 1999-01-11
US13276099P 1999-05-06 1999-05-06
US60/132,760 1999-05-06

Publications (3)

Publication Number Publication Date
WO2000042068A2 WO2000042068A2 (en) 2000-07-20
WO2000042068A3 true WO2000042068A3 (en) 2000-12-21
WO2000042068A9 WO2000042068A9 (en) 2002-04-11

Family

ID=26813196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/000372 WO2000042068A2 (en) 1999-01-11 2000-01-07 Hiv related peptides

Country Status (3)

Country Link
EP (1) EP1159297A2 (en)
AU (1) AU2603100A (en)
WO (1) WO2000042068A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050420A2 (en) * 2004-11-01 2006-05-11 Trinity Biosystems, Inc. Chimeric immunogens that comprise ovalbumin
WO2010096042A1 (en) * 2008-10-30 2010-08-26 Dana-Farber Cancer Institute Mimotopes of hiv env

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009872A2 (en) * 1989-12-13 1991-07-11 Univax Biolog Inc Hiv-1 env fragment fusion protein
EP0471407A2 (en) * 1990-08-13 1992-02-19 Merck & Co. Inc. New embodiments of the HIV principal neutralizing determinant
WO1994002626A1 (en) * 1992-07-20 1994-02-03 Merck & Co., Inc. Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
WO1994002614A1 (en) * 1992-07-16 1994-02-03 Medical Research Council PEPTIDES THAT MIMIC gp120 HIV EPITOPE
EP0673948A1 (en) * 1994-02-23 1995-09-27 BEHRINGWERKE Aktiengesellschaft Pepticles derived from a retrovirus of the HIV-group and their use
WO1999066046A1 (en) * 1998-06-12 1999-12-23 Aventis Pasteur Hiv virus mimotopes
WO1999066957A2 (en) * 1998-06-20 1999-12-29 United Biomedical Inc. Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009872A2 (en) * 1989-12-13 1991-07-11 Univax Biolog Inc Hiv-1 env fragment fusion protein
EP0471407A2 (en) * 1990-08-13 1992-02-19 Merck & Co. Inc. New embodiments of the HIV principal neutralizing determinant
WO1994002614A1 (en) * 1992-07-16 1994-02-03 Medical Research Council PEPTIDES THAT MIMIC gp120 HIV EPITOPE
WO1994002626A1 (en) * 1992-07-20 1994-02-03 Merck & Co., Inc. Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
EP0673948A1 (en) * 1994-02-23 1995-09-27 BEHRINGWERKE Aktiengesellschaft Pepticles derived from a retrovirus of the HIV-group and their use
WO1999066046A1 (en) * 1998-06-12 1999-12-23 Aventis Pasteur Hiv virus mimotopes
WO1999066957A2 (en) * 1998-06-20 1999-12-29 United Biomedical Inc. Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BOOTS LJ ET AL.,: "Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 13, 10 December 1997 (1997-12-10), pages 1549-1559, XP000907201 *
BUCHBINDER S AND VITTINGHOFF E: "HIV-infected long-term nonprogressors: epidemiology, mechanisms of delayed progression, and clinical and research implications", MICROBES AND INFECTION, vol. 1, November 1999 (1999-11-01), pages 1113 - 1120, XP000911184 *
CONF ADV AIDS VACCINE DEV, 4 May 1997 (1997-05-04), pages p109 *
COTROPIA J ET AL.,: "A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates.", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, vol. 12, no. 3, 1996, pages 221-232, XP000910872 *
DATABASE AIDSLINE BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; BONNYCASTLE L ET AL.,: "The identification of "HIV-1-mimic" peptides using antibodies from the sera of HIV-1 infected, long-term non-progressors.", XP002139103 *
D'SOUZA M.P. ET AL.,: "Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies fro clinical trials", JOURNAL OF INFECTIOUS DISEASES, vol. 175, 1997, pages 1056-1062, XP000910884 *
FELICI F ET AL: "SELECTION OF ANTIBODY LIGANDS FROM A LARGE LIBRARY OF OLIGOPEPTIDESEXPRESSED ON A MULTIVALENT EXPOSITION VECTOR", JOURNAL OF MOLECULAR BIOLOGY,GB,LONDON, vol. 222, no. 2, 1 January 1991 (1991-01-01), pages 301 - 310, XP000373977, ISSN: 0022-2836 *
HAESEVELDE VANDEN M ET AL: "GENOMIC CLONING AND COMPLETE SEQUENCE ANALYSIS OF A HIGHLY DIVERGENT AFRICAN HUMAN IMMUNODEFICIENCY VIRUS ISOLATE", JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 68, no. 3, 1 March 1994 (1994-03-01), pages 1586 - 1596, XP002034445, ISSN: 0022-538X *
HOGERVORST E ET AL.,: "Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: Low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels", JOURNAL OF INFECTIOUS DISEASES, vol. 171, no. 4, 1995, pages 811-821, XP000910818 *
IDA SETSUKO ET AL: "HIV type 1 V3 variation dynamics in vivo: Long-term persistence of non-syncytium-inducing genotypes and transient presence of syncytium-inducing genotypes during the course of progressive AIDS.", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 13, no. 18, 10 December 1997 (1997-12-10), pages 1597 - 1609, XP000925917, ISSN: 0889-2229 *
MARZO VERONESE DI F ET AL: "STRUCTURAL MIMICRY AND ENHANCED IMMUNOGENICITY OF PEPTIDE EPITOPES DISPLAYED ON FILAMENTOUS BACTERIOPHAGE. THE V3 LOOP OF HIV-1 GP120", JOURNAL OF MOLECULAR BIOLOGY,GB,LONDON, vol. 243, no. 2, 1994, pages 167 - 172, XP000877088, ISSN: 0022-2836 *
MONTEFIORI DAVID C ET AL.,: "Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.", JOURNAL OF INFECTIOUS DISEASES, vol. 173, no. 1, 1996, pages 60-67, XP000910864 *
PANTALEO G ET AL.,: "Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.", NEW ENGLAND JOURNAL OF MEDICINE, vol. 332, 1995, pages 209-216, XP000910863 *
RUSCONI S ET AL.,: "Patterns of in vitro anti-human immunodeficiency virus type 1 antibody production in long-term nonprogressors.", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 85, no. 3, 1997, pages 320-323, XP000910865 *
TORAN JL ET AL.,: "Molecular analysis of HIV-1 gp120 antibody response using isotype IgM and IgG phage display libraries from a long-term non-progressor HIV-1-infected individual.", EUR J IMMUNOL, vol. 29 (9), September 1999 (1999-09-01), pages 2666-75, XP000913460 *

Also Published As

Publication number Publication date
WO2000042068A9 (en) 2002-04-11
AU2603100A (en) 2000-08-01
WO2000042068A2 (en) 2000-07-20
EP1159297A2 (en) 2001-12-05

Similar Documents

Publication Publication Date Title
WO1999033868A3 (en) Human papillomavirus vaccine
WO1999010375A3 (en) Vaccine against hpv
WO2002069949A3 (en) Combination therapy for reduction of toxycity of chemotherapeutic agents
ATE269321T1 (en) MEDICINAL PRODUCTS FOR VIRAL DISEASES
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
WO2003015702A3 (en) Epitopes of human immunodeficiency virus-1
AU2001292125A1 (en) Genetic factors affecting the outcome of viral infections
WO2000042068A3 (en) Hiv related peptides
AU5499996A (en) Chlamydia vaccines
WO2000015634A3 (en) Hiv protease inhibitors
AU2913400A (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
AU2002314331A1 (en) Bacteriophage preparation for the treatment of intracellular bacterial infection
WO2004031209A3 (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
AU2002229850A1 (en) Polypeptide inducing hiv-neutralising antibodies
AU2001287820A1 (en) Use of lipopeptides for immunotherapy of hiv-positive subjects
AU7438301A (en) The use of synthetic, non-hormonal 21-aminosteroids, derivatives, metabolites and precursors thereof in the treatment of viral infections
EP0379295A3 (en) Anti-tryptase antibody and composition for treatment of aids using the same
WO2002069691A3 (en) Immunogenic hiv peptides for use as reagents and vaccines
AU2002219290A1 (en) Proteinic antigens inducing antibodies neutralising hiv virus
AU2002338856A1 (en) Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
ZA200108398B (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.
AP2003002852A0 (en) Natural antibodies active against HIV virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000904245

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09869003

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000904245

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/10-10/10; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2000904245

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载